ILMN Earnings

ILMN reported its earnings on 2026-04-30, showcasing a revenue of 1.09B against an estimate of 1.08B, resulting in a 1.02% surprise. The EPS was 1.15, surpassing the expected 1.05 by 9.52%. The stock experienced a 7.13% price change on the earnings day and a 12.5% change over the next five days, reflecting market reactions to the results.

Following ILMN's earnings announcement on 2026-04-30, the stock price moved by 7.13% on the day of the release. Over the subsequent five days, it saw a 12.5% change. Historically, ILMN's stock price tends to shift by an average of 0.71% in the 10 days leading up to earnings and -1.88% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate ILMN's annual revenue to reach 1.08B, while the EPS is projected at 1.24. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ILMN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ILMN's stock price typically moves by 0.71% in the 10 days before its earnings and -1.88% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 1.24 and revenue of 1.08B.

The earnings call highlights strong financial performance with a 19% increase in EPS and improved margins. Management expressed optimism about clinical growth and incremental instrument placements, despite not raising organic growth guidance. The Q&A section reassures strong demand and no market freezing, with expectations of margin improvements later in the year. Although some vague responses were noted, the overall sentiment is positive with raised guidance and strategic growth in clinical and spatial markets.